Evogene (EVGN) has released an update.
Evogene Ltd. has reported substantial improvements in its Q1 2024 financial results, with revenue increasing to $4.2M from $0.6M in the previous year and a reduced net loss of $3.8M. The company has streamlined operations, resulting in significant cost savings, and established new partnerships, leveraging their proprietary AI tech-engines to accelerate the development of life-science products across its subsidiaries. These strategic moves are expected to drive continued growth and fulfill existing product orders by the end of 2024.
For further insights into EVGN stock, check out TipRanks’ Stock Analysis page.
